Ixazomib

• Description:

  Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM) .

• Product Name Alternative:

  MLN2238

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Autophagy; Proteasome

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/MLN2238.html

• Purity:

  99.85

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  OB([C@@H](NC(CNC(C1=CC(Cl)=CC=C1Cl)=O)=O)CC(C)C)O

• Molecular Formula:

  C14H19BCl2N2O4

• Molecular Weight:

  361.03

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Friedman JR, et al. Anticancer Activity of Natural and Synthetic Capsaicin Analogs. J Pharmacol Exp Ther. 2018 Mar;364 (3) :462-473.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [1072833-77-2]